Health

Sanofi's MS Drug Tolebrutinib Falls Short in Relapsing Trials

Sep 2, 2024 1 min read

Jump to Summary

Sanofi's leading multiple sclerosis (MS) drug candidate, tolebrutinib, has failed to meet the primary goals in two late-stage trials aimed at treating relapsing forms of the disease. The drug did not show significant efficacy in reducing relapse rates compared to the company's existing MS medication, Aubagio. This outcome has raised concerns about the prospects of tolebrutinib and its class of drugs, particularly due to potential links to liver damage and uncertain overall efficacy.

Despite these setbacks, a separate third late-stage trial indicated that tolebrutinib was effective in treating a progressive form of MS, a less common variant that currently lacks treatment options. Sanofi plans to discuss these mixed results with regulators and aims to file for approval by the end of 2024. The company is actively seeking new opportunities in the MS treatment landscape to offset revenue losses following the recent expiration of Aubagio's patent protection. CEO Paul Hudson has been working to regain investor confidence by boosting drug development spending and addressing challenges within the pharma pipeline.

#business

Summary

Other news in health

China to Permit Foreign-Owned Hospitals in Major Urban Centers

China has announced that it will fully open its manufacturing sector to foreign investments and allow more room for foreign capital in its health sector starting from November 1. The National Development and Reform Commission (NDRC) will remove the last remaining limits on overseas investments in the manufacturing sector and

Couche-Tard Renews Bid for Seven & i After $38.5 Billion Rejection

Alimentation Couche-Tard is making a renewed effort to acquire Seven & i Holdings, the Japanese operator of 7-Eleven, after its initial $38.5 billion offer was rejected. The Canadian convenience retailer plans to write to Seven & i in the coming days to reiterate its interest and may even take

New vaccine emerges for a little-known deadly virus affecting over-75s

The NHS has launched its first-ever RSV vaccination campaign aimed at protecting vulnerable groups from the respiratory syncytial virus, which can cause severe breathing difficulties in young children and older adults. The campaign focuses on adults aged 75 to 79 and pregnant women, who can pass on RSV antibodies to

YouTuber Nikocado Avocado Stuns Fans With 113kg Weight Loss in 7 Months

Nicholas Perry, known as Nikocado Avocado, has returned to YouTube after a seven-month hiatus, revealing a significant weight loss of 250 pounds. The transformation has sparked widespread discussion on social media platforms like X (formerly Twitter) and Reddit. While many fans expressed admiration, others speculated that his rapid weight loss